Clinical trial
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or…
NCT00377936 · MediGene, Industry · Completed
Key facts
| NCT number | NCT00377936 |
|---|---|
| Title | EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas |
| Official title | A Controlled, Randomized, Open Label Phase II Trial to Evaluate Safety and Efficacy of a 1st Line Combination Treatment With Weekly Infusions of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG-1) in Three Dose Levels Compared With Gemcitabine Monotherapy in… |
| Lead sponsor | MediGene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma, Metastasis, Pancreas Neoplasms |
| Intervention type | Drug |
| Interventions | Gemcitabine alone, EndoTAG-1 and Gemcitabine |
| Enrollment | 212 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 19, 2006 |
| Last update posted | Nov 14, 2008 |
| Countries | Czechia, Hungary, Ukraine |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: